TherapeuticsMD logo
TherapeuticsMD TXMD
$ 2.21 0.22%
report update icon

Quarterly report 2026-Q2
added 08-11-2026

TherapeuticsMD Cash Flow 2025-2009 | TXMD

Brief cash flow overview of TherapeuticsMD

Cash flows are assessed across five available annual periods spanning 2016 to 2020.

Cash from operations is below zero at -$159.5 million, increasing dependence on cash reserves or outside financing.

Operating cash flow was positive in only 0 of five periods. Cash generation remains unstable.

Working capital needs increased $21.1 million, or 32.5% of sales. This may restrain cash conversion.

What the cash flows show

TherapeuticsMD's cash flows remain vulnerable. Negative or unstable generation materially reduces financial flexibility.

Annual Cash Flow TherapeuticsMD

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009

Operating Cash Flow

- - - - - -159 M -166 M -107 M -76.2 M -69.1 M -79 M -45.5 M -20.8 M -12.7 M -4.97 M - -

Depreciation & Amortization

384 K 509 K 922 K 1.19 M 736 K 4.07 M 1.39 M 294 K 213 K 132 K 62.4 K 52.5 K 58.1 K 56.3 K 54.8 K - -

Accounts Payables

377 K 258 K 27 K 2.16 M 3.37 M 21.1 M 19.2 M 22.7 M 4.1 M 7.36 M 3.13 M 6.33 M 2.11 M 1.64 M 307 K - -

Accounts Receivables

- - - - - 32.4 M 24.4 M 11.1 M 4.33 M 4.5 M 3.05 M 2.15 M 1.69 M 607 K 26.7 K - -

Total Inventories

- - - - - 7.99 M 11.9 M 3.27 M 1.49 M 1.08 M 690 K 1.18 M 1.04 M 1.62 M 588 K - -

All numbers in USD currency

Quarterly Cash Flow TherapeuticsMD

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- - - - - - - - - - - - - -8.7 M - -63.8 M -44.9 M -17.9 M - -103 M -64.9 M -38.4 M - -129 M -95.1 M -39.1 M - -115 M -88.7 M -38.2 M - -78.7 M -44.6 M -19.6 M - -55.4 M -38.7 M -20.5 M - -53.5 M -34.7 M -19.4 M - -62.4 M -44 M -19.1 M - -30.2 M -18.8 M -8.71 M - -16 M -10.7 M -3.51 M - -8.73 M -5.65 M -2.45 M - -3.08 M -1.56 M -761 K

Depreciation & Amortization

13 K 94 K - 96 K 96 K 95 K - 96 K 180 K 133 K - - 128 K 27 K - 200 K 200 K 329 K - 3.09 M 2.06 M 1.02 M - 259 K 257 K 1.01 M - 142 K 115 K 107 K - 73.3 K 65.6 K 59.6 K - 54.1 K 53.2 K 49.7 K - 40.5 K 24.3 K 19.6 K - 16.5 K 14.3 K 13.6 K - 12.7 K 14.1 K 13.1 K - 32.4 K 10.6 K 7.96 K 28.8 K 14.8 K 14.5 K 14.6 K - 41.1 K 27.4 K 13.7 K

Accounts Payables

377 K 15 K 258 K 263 K 350 K 176 K 258 K - 143 K - 27 K 696 K 1.51 M 2.33 M 2.16 M 13.4 M 14 M 20.8 M 20.3 M 19.6 M 14.6 M 10.3 M 21.1 M 21.1 M 21.1 M 21.1 M 19.2 M 19.2 M 19.2 M 19.2 M 22.7 M 22.7 M 22.7 M 22.7 M 4.1 M 4.1 M 4.1 M 4.1 M 7.36 M 7.36 M 7.36 M 7.36 M 3.13 M 3.13 M 3.13 M 3.13 M 6.33 M 6.33 M 6.33 M 6.33 M 2.11 M 2.11 M 2.11 M 2.11 M 1.64 M 1.64 M 1.64 M 1.64 M 307 K 307 K 307 K 307 K

Accounts Receivables

- - - - - - - - - - - - - - - 32.2 M 45.8 M 35.4 M 36.2 M 37.4 M 33.5 M 33.7 M 32.4 M 32.4 M 32.4 M 32.4 M 24.4 M 24.4 M 24.4 M 24.4 M 11.1 M 11.1 M 11.1 M 11.1 M 4.33 M 4.33 M 4.33 M 4.33 M 4.5 M 4.5 M 4.5 M 4.5 M 3.05 M 3.05 M 3.05 M 3.05 M 2.15 M 2.15 M 2.15 M 2.15 M 1.69 M 1.69 M 1.69 M 1.69 M 714 K 607 K 607 K 607 K 26.7 K 26.7 K 26.7 K 26.7 K

Total Inventories

- - - - - - - - - - - - - - - 6.7 M 6.15 M 8.97 M 7.62 M 7.36 M 7.57 M 7.35 M 7.99 M 7.99 M 7.99 M 7.99 M 11.9 M 11.9 M 11.9 M 11.9 M 3.27 M 3.27 M 3.27 M 3.27 M 1.49 M 1.49 M 1.49 M 1.49 M 1.08 M 1.08 M 1.08 M 1.08 M 690 K 690 K 690 K 690 K 1.18 M 1.18 M 1.18 M 1.18 M 1.04 M 1.04 M 1.04 M 1.04 M 1.62 M 1.62 M 1.62 M 1.62 M 588 K 588 K 588 K 588 K

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company TherapeuticsMD, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Drug manufacturers sector

Issuer Price % 24h Market Cap Country
PLx Pharma PLx Pharma
PLXP
- -27.8 % $ 2.56 M usaUSA
HEXO Corp. HEXO Corp.
HEXO
- 2.45 % $ 38.1 M canadaCanada
Calliditas Therapeutics AB (publ) Calliditas Therapeutics AB (publ)
CALT
- -0.1 % $ 2.03 B schwedenSchweden
Athenex Athenex
ATNX
- -23.39 % $ 1.76 M usaUSA
OrganiGram Holdings OrganiGram Holdings
OGI
$ 1.16 0.42 % $ 111 M canadaCanada
Sundial Growers Sundial Growers
SNDL
$ 1.44 1.77 % $ 372 M canadaCanada
Endo International plc Endo International plc
ENDP
- - $ 28.9 M irlandaIrlanda
Perrigo Company plc Perrigo Company plc
PRGO
$ 14.92 4.56 % $ 2.07 B usaUSA
Canopy Growth Corporation Canopy Growth Corporation
CGC
$ 0.97 0.17 % $ 289 M canadaCanada
Aurora Cannabis Aurora Cannabis
ACB
$ 3.95 1.54 % $ 217 M canadaCanada
Aerie Pharmaceuticals Aerie Pharmaceuticals
AERI
- - $ 754 M usaUSA
AcelRx Pharmaceuticals AcelRx Pharmaceuticals
ACRX
- 7.5 % $ 6.35 M usaUSA
Adamis Pharmaceuticals Corporation Adamis Pharmaceuticals Corporation
ADMP
- 0.86 % $ 117 M usaUSA
Agile Therapeutics Agile Therapeutics
AGRX
- 10.11 % $ 58.2 M usaUSA
Alimera Sciences Alimera Sciences
ALIM
- - $ 142 M usaUSA
Assertio Holdings Assertio Holdings
ASRT
- - $ 150 M usaUSA
Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc
AVDL
- - $ 2.06 B franceFrance
Bausch Health Companies Bausch Health Companies
BHC
$ 6.56 5.56 % $ 2.43 B canadaCanada
China Pharma Holdings China Pharma Holdings
CPHI
$ 0.82 0.1 % $ 3.52 M chinaChina
Cumberland Pharmaceuticals Cumberland Pharmaceuticals
CPIX
$ 6.79 0.59 % $ 101 M usaUSA
Cronos Group Cronos Group
CRON
$ 3.26 0.62 % $ 1.25 B canadaCanada
Catalent Catalent
CTLT
- - $ 11.5 B usaUSA
DURECT Corporation DURECT Corporation
DRRX
- - $ 50.1 M usaUSA
Emergent BioSolutions Emergent BioSolutions
EBS
$ 6.21 0.08 % $ 332 M usaUSA
Eagle Pharmaceuticals Eagle Pharmaceuticals
EGRX
- -39.89 % $ 27.7 M usaUSA
Evolus Evolus
EOLS
$ 9.3 2.76 % $ 600 M usaUSA
Evoke Pharma Evoke Pharma
EVOK
- - $ 36.6 M usaUSA
Harrow Health Harrow Health
HROW
$ 38.54 0.73 % $ 1.42 B usaUSA
Jupiter Wellness Jupiter Wellness
JUPW
- - $ 33.6 M usaUSA
Lannett Company Lannett Company
LCI
- 1.15 % $ 7.11 M usaUSA
Neoleukin Therapeutics Neoleukin Therapeutics
NLTX
- - $ 193 M canadaCanada
OptiNose OptiNose
OPTN
- - $ 1.08 B usaUSA
Organogenesis Holdings Organogenesis Holdings
ORGO
$ 1.71 4.27 % $ 217 M usaUSA
Pacira BioSciences Pacira BioSciences
PCRX
$ 26.35 0.08 % $ 1.17 B usaUSA
PetIQ PetIQ
PETQ
- 1.64 % $ 400 M usaUSA
ProPhase Labs ProPhase Labs
PRPH
- - $ 5.07 M usaUSA
Radius Health Radius Health
RDUS
- - $ 1.42 B usaUSA
Recro Pharma Recro Pharma
REPH
- -4.76 % $ 65.3 M usaUSA
Relmada Therapeutics Relmada Therapeutics
RLMD
$ 4.43 1.37 % $ 175 M usaUSA
Rockwell Medical Rockwell Medical
RMTI
$ 7.99 1.31 % $ 287 M usaUSA
SCYNEXIS SCYNEXIS
SCYX
$ 5.3 0.47 % $ 265 M usaUSA
Solid Biosciences Solid Biosciences
SLDB
$ 10.25 1.31 % $ 897 M usaUSA
Sonoma Pharmaceuticals Sonoma Pharmaceuticals
SNOA
$ 1.33 0.38 % $ 2.24 M usaUSA
Tricida Tricida
TCDA
- - $ 3.25 M usaUSA
Tilray Tilray
TLRY
$ 4.5 0.22 % $ 4.01 B canadaCanada
Veru Veru
VERU
$ 2.64 0.94 % $ 38.7 M usaUSA
Viatris Viatris
VTRS
$ 16.88 0.03 % $ 19.4 B usaUSA
cbdMD cbdMD
YCBD
$ 0.5 4.68 % $ 2.01 M usaUSA
Zomedica Corp. Zomedica Corp.
ZOM
- -0.21 % $ 98 M usaUSA